NZ735044A - Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof - Google Patents
Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereofInfo
- Publication number
- NZ735044A NZ735044A NZ735044A NZ73504416A NZ735044A NZ 735044 A NZ735044 A NZ 735044A NZ 735044 A NZ735044 A NZ 735044A NZ 73504416 A NZ73504416 A NZ 73504416A NZ 735044 A NZ735044 A NZ 735044A
- Authority
- NZ
- New Zealand
- Prior art keywords
- condensed ring
- preparation
- ring derivative
- pharmaceutical composition
- derivative
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 abstract 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract 1
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/36—Benzo-cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510131828 | 2015-03-24 | ||
| PCT/CN2016/073043 WO2016150255A1 (zh) | 2015-03-24 | 2016-02-01 | 稠环衍生物、其制备方法、中间体、药物组合物及应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ735044A true NZ735044A (en) | 2018-10-26 |
Family
ID=56977003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ735044A NZ735044A (en) | 2015-03-24 | 2016-02-01 | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10100015B2 (enExample) |
| EP (1) | EP3275867B1 (enExample) |
| JP (1) | JP6449482B2 (enExample) |
| KR (1) | KR102087918B1 (enExample) |
| CN (3) | CN108516958B (enExample) |
| AU (1) | AU2016236669B2 (enExample) |
| CA (1) | CA2980484C (enExample) |
| IL (1) | IL254098B (enExample) |
| MX (1) | MX383376B (enExample) |
| NZ (1) | NZ735044A (enExample) |
| RU (1) | RU2683566C1 (enExample) |
| SG (1) | SG11201706869XA (enExample) |
| TW (2) | TWI666201B (enExample) |
| WO (1) | WO2016150255A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108516958B (zh) | 2015-03-24 | 2020-07-17 | 上海璎黎药业有限公司 | 稠环衍生物、其制备方法、中间体、药物组合物及应用 |
| KR102591886B1 (ko) * | 2015-07-21 | 2023-10-20 | 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. | 축합고리 피리미딘계 화합물, 중간체, 이의 제조 방법, 조성물 및 응용 |
| CN107286156A (zh) * | 2016-04-05 | 2017-10-24 | 江苏新元素医药科技有限公司 | 新型urat1抑制剂及其在医药上的应用 |
| CA3025078C (en) * | 2016-05-23 | 2021-04-13 | Cstone Pharmaceutical (Suzhou) Co., Ltd. | Thiophene, manufacturing method thereof, and pharmaceutical application of same |
| CN106146533B (zh) * | 2016-07-14 | 2018-04-03 | 华润赛科药业有限责任公司 | 含硫杂环羧酸类衍生物、其制备方法和应用 |
| CN106083847B (zh) * | 2016-08-03 | 2018-10-30 | 山东大学 | 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用 |
| CN108084186B (zh) * | 2016-11-16 | 2021-06-25 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| WO2018090921A1 (zh) * | 2016-11-16 | 2018-05-24 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| CN108033909A (zh) * | 2017-12-20 | 2018-05-15 | 北京六合宁远科技有限公司 | 一种6-甲基-4-溴-异喹啉的制备方法 |
| CN109608432B (zh) * | 2018-12-17 | 2022-10-11 | 江苏艾立康医药科技有限公司 | 作为urat1抑制剂的噻吩类衍生物 |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| CN111303161B (zh) * | 2020-04-14 | 2021-01-05 | 遵义医科大学珠海校区 | 嘧啶并氮杂环类化合物及其用途 |
| CN111763218B (zh) * | 2020-07-14 | 2021-05-28 | 山东大学 | 一种噻吩并嘧啶酮巯乙酸类衍生物及其制备方法与应用 |
| WO2023131017A1 (zh) | 2022-01-04 | 2023-07-13 | 上海璎黎药业有限公司 | 一种稠环衍生物的晶型、其制备方法及其应用 |
| CN116465985B (zh) * | 2023-03-03 | 2024-12-10 | 连云港杰瑞药业有限公司 | 一种气相色谱法检测α-核糖甲磺酸酯中残留溶剂的方法 |
| WO2024209363A1 (en) | 2023-04-06 | 2024-10-10 | Pfizer Inc. | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
| CN118955327A (zh) * | 2024-06-26 | 2024-11-15 | 安徽大学 | 一种4-溴-1-萘甲腈的合成方法 |
| CN118878551A (zh) * | 2024-07-08 | 2024-11-01 | 安徽大学 | 一种4-溴噻吩并[2,3-c]吡啶-2-羧酸乙酯的制备方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3558655A (en) * | 1969-06-25 | 1971-01-26 | Parke Davis & Co | Benzo(b)thiopheneacetic acid compounds |
| US4224330A (en) | 1979-09-13 | 1980-09-23 | Zoecon Corporation | Esters and thiolesters of benzothienyl acids |
| AUPO282896A0 (en) | 1996-10-07 | 1996-10-31 | Fujisawa Pharmaceutical Co., Ltd. | Novel compounds |
| ATE339406T1 (de) | 1999-09-23 | 2006-10-15 | Astrazeneca Ab | Chinazoline verbindungen als heilmittel |
| US6987118B2 (en) | 2003-05-21 | 2006-01-17 | Pfizer Inc. | Tetrahydroisoquinoline derivatives as PPAR-alpha activators |
| TWI328009B (en) * | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| ATE370941T1 (de) * | 2003-11-20 | 2007-09-15 | Lilly Co Eli | Modulatoren des vitamin-d-rezeptors |
| EP1697427B1 (en) * | 2003-12-22 | 2008-12-24 | Basell Polyolefine GmbH | Metallocene compounds |
| SE0400440D0 (sv) * | 2004-02-25 | 2004-02-25 | Active Biotech Ab | Novel Cinnamic Amides |
| GB0426313D0 (en) * | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
| US8916550B2 (en) * | 2005-05-09 | 2014-12-23 | Hydra Biosciences, Inc. | Compounds for modulating TRPV3 function |
| CN101360743A (zh) * | 2006-01-30 | 2009-02-04 | Irm责任有限公司 | 作为ppar调节剂的多环的1,2,3,4-四氢-异喹啉衍生物和包含它们的组合物 |
| BRPI0708782A2 (pt) | 2006-03-16 | 2011-06-14 | Astellas Pharma Inc | derivado de triazol ou um sal deste |
| US7960567B2 (en) * | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
| CA2722606A1 (en) * | 2008-05-05 | 2009-11-12 | Amgen Inc. | Urea compounds as gamma secretase modulators |
| US8809382B2 (en) * | 2009-05-04 | 2014-08-19 | The Royal Institution For The Advancement Of Learning/Mcgill University | 5-oxo-ETE receptor antagonist compounds |
| TW201116281A (en) | 2009-08-06 | 2011-05-16 | Astellas Pharma Inc | N atom containing ring acylguanidine derivatives |
| NZ705135A (en) * | 2010-05-26 | 2017-10-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
| WO2011159840A2 (en) * | 2010-06-16 | 2011-12-22 | Ardea Biosciences, Inc. | Phenylthioacetate compounds, compositions and methods of use |
| US20140005224A1 (en) | 2010-10-27 | 2014-01-02 | Bayer Intellectual Property Gmbh | Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides |
| EP2669270B1 (en) * | 2011-01-28 | 2018-01-03 | Sato Pharmaceutical Co., Ltd. | Indole-related compounds as urat1 inhibitors |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5878178B2 (ja) * | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | １，２，４−トリアジン−６−カルボキサミド誘導体 |
| KR102148355B1 (ko) * | 2012-07-27 | 2020-08-26 | 사토 파머슈티컬 가부시키가이샤 | 디플루오로메틸렌 화합물 |
| AR093519A1 (es) * | 2012-11-20 | 2015-06-10 | Hoffmann La Roche | 1,6-naftiridinas sustituidas |
| RU2673549C2 (ru) * | 2013-05-03 | 2018-11-28 | Ф. Хоффманн-Ля Рош Аг | Производные изохинолина, стимулирующие нейрогенез |
| US9550770B2 (en) | 2013-08-23 | 2017-01-24 | Neupharma, Inc. | Substituted quinazolines for inhibiting kinase activity |
| CN107567443B (zh) * | 2014-12-24 | 2023-04-28 | 株式会社Lg化学 | 作为gpr120激动剂的联芳基衍生物 |
| CN108516958B (zh) | 2015-03-24 | 2020-07-17 | 上海璎黎药业有限公司 | 稠环衍生物、其制备方法、中间体、药物组合物及应用 |
-
2016
- 2016-02-01 CN CN201810188236.0A patent/CN108516958B/zh active Active
- 2016-02-01 CA CA2980484A patent/CA2980484C/en active Active
- 2016-02-01 NZ NZ735044A patent/NZ735044A/en unknown
- 2016-02-01 AU AU2016236669A patent/AU2016236669B2/en active Active
- 2016-02-01 CN CN201810188235.6A patent/CN108299425B/zh active Active
- 2016-02-01 WO PCT/CN2016/073043 patent/WO2016150255A1/zh not_active Ceased
- 2016-02-01 JP JP2017550129A patent/JP6449482B2/ja active Active
- 2016-02-01 EP EP16767632.9A patent/EP3275867B1/en active Active
- 2016-02-01 SG SG11201706869XA patent/SG11201706869XA/en unknown
- 2016-02-01 US US15/559,181 patent/US10100015B2/en active Active
- 2016-02-01 MX MX2017012009A patent/MX383376B/es unknown
- 2016-02-01 RU RU2017134044A patent/RU2683566C1/ru active
- 2016-02-01 KR KR1020177029920A patent/KR102087918B1/ko active Active
- 2016-02-01 CN CN201610071297.XA patent/CN106008340B/zh active Active
- 2016-03-24 TW TW106139600A patent/TWI666201B/zh active
- 2016-03-24 TW TW105109178A patent/TWI675026B/zh active
-
2017
- 2017-08-22 IL IL254098A patent/IL254098B/en active IP Right Grant
-
2018
- 2018-05-22 US US15/985,848 patent/US10100016B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108299425B (zh) | 2020-09-18 |
| SG11201706869XA (en) | 2017-09-28 |
| EP3275867A4 (en) | 2018-01-31 |
| TW201808909A (zh) | 2018-03-16 |
| RU2683566C1 (ru) | 2019-03-29 |
| EP3275867B1 (en) | 2020-06-10 |
| TWI666201B (zh) | 2019-07-21 |
| CN108299425A (zh) | 2018-07-20 |
| MX383376B (es) | 2025-03-13 |
| HK1226055A1 (zh) | 2017-09-22 |
| CN106008340A (zh) | 2016-10-12 |
| US20180265476A1 (en) | 2018-09-20 |
| JP2018509451A (ja) | 2018-04-05 |
| AU2016236669B2 (en) | 2018-11-08 |
| CN106008340B (zh) | 2020-03-17 |
| CA2980484C (en) | 2019-11-26 |
| TW201641491A (zh) | 2016-12-01 |
| TWI675026B (zh) | 2019-10-21 |
| KR20170123705A (ko) | 2017-11-08 |
| WO2016150255A1 (zh) | 2016-09-29 |
| KR102087918B1 (ko) | 2020-03-12 |
| MX2017012009A (es) | 2018-06-06 |
| US10100016B2 (en) | 2018-10-16 |
| CN108516958A (zh) | 2018-09-11 |
| IL254098B (en) | 2020-03-31 |
| US20180072678A1 (en) | 2018-03-15 |
| CA2980484A1 (en) | 2016-09-29 |
| JP6449482B2 (ja) | 2019-01-09 |
| IL254098A0 (en) | 2017-10-31 |
| AU2016236669A1 (en) | 2017-09-21 |
| EP3275867A1 (en) | 2018-01-31 |
| US10100015B2 (en) | 2018-10-16 |
| CN108516958B (zh) | 2020-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ735044A (en) | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| EP3675859A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE | |
| EP3448874A4 (en) | COMPOSITIONS FOR TREATING A DISEASE | |
| EP3448987A4 (en) | COMPOSITIONS FOR TREATING A DISEASE | |
| PH12016502255A1 (en) | Combination | |
| PH12016501441A1 (en) | Chimeric alkaline phosphate-like proteins | |
| MX2017009417A (es) | Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas. | |
| MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
| HK1259441A1 (zh) | 包含btk抑制剂的制剂/组合物 | |
| HK1246810A1 (zh) | Lingo-1对抗药及用於治疗脱髓鞘疾病的用途 | |
| MX2017001103A (es) | Derivados de indolizina que son aplicables a enfermedades neurodegenerativas. | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| ZA201805407B (en) | Composition for the prevention or treatment of neurodegenerative diseases. | |
| EP3192875A4 (en) | Sustained-release pharmaceutical composition for treating and preventing ophthalmic diseases | |
| EP3156055A4 (en) | Pharmaceutical composition for preventing or treating muscular weakness-related diseases, containing butylpyridinium or derivative thereof | |
| EP4339192A3 (en) | Compounds and compositions for the treatment of cancer | |
| ZA201703467B (en) | Methods of treating ocular conditions | |
| EP3275450A4 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| IN2014CH00840A (enExample) | ||
| EP3169405A4 (en) | Methods, compounds, and compositions for the treatment of musculoskeletal diseases | |
| GB201518456D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases | |
| EP3501524A4 (en) | USE OF PHYTOSPHINGOSINE-1-PHOSPHATE OR A DERIVATIVE THEREOF AS AN IMMUNE ACTIVATOR OR PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DEMENTIA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2021 BY PETRA OLK Effective date: 20200123 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2022 BY DENNEMEYER + CO. Effective date: 20210125 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2023 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20220124 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2024 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20230123 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2025 BY JING LEI Effective date: 20240125 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2026 BY ACUMASS Effective date: 20250121 |